Clinical Research Directory
Browse clinical research sites, groups, and studies.
ST2 for the Management of Heart Failure - STADE-HF
Sponsor: University Hospital, Montpellier
Summary
Heart failure (HF) is a severe disease, burdened with a poor prognosis (30% mortality at 2 years, 30% of rehospitalization within 1 month). It is also a major cause of health burden representing between 1.5 and 2 billions euros per year in France. Approximately 75% of these costs are due to hospitalization. Besides physical examination and echocardiography, biology may help refine the diagnosis, but also could provide powerful prognostic parameters. This study aims to assess the value of ST2 in the management of patients admitted for HF to reduce readmission at one month.
Official title: Interest of ST2 to Diagnosis and Management of Patients With Heart Failure (HF)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
123
Start Date
2017-01-19
Completion Date
2019-04-26
Last Updated
2026-06-12
Healthy Volunteers
No
Interventions
Conventional strategy
Conventional strategy to manage the patients with HF, following the international guidelines.
ST2-guided strategy
patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
Locations (1)
University Regional Hospital Arnaud de Villeneuve
Montpellier, Languedoc-Roussillon, France